Police seize €57 million in illegal Ozempic, peptides, and other black market drugs in global bust
Between December and May, authorities in 90 countries – including 16 in the European Union – confiscated 50.4 million doses of drugs that were either fake, misbranded, unapproved, or diverted, according to the International Criminal Police Organization (Interpol), which coordinated the operation.
In Europe, many of the seizures were for counterfeit or unapproved weight loss drugs and peptide supplements, which Interpol said reflects the surging popularity of 'cosmetic and performance-enhancing' pharmaceuticals.
These drugs are so widely available online and on social media that police are having a hard time keeping up, Alfonso Mejuto Rodríguez, Interpol's pro tempore assistant director of criminal networks, told Euronews Health.
Related
Rising deaths, fake pills, gang violence: How the EU is struggling to cope with illegal drug problem
'It's not even necessary to go to the dark web [because] there are a lot of advertisements online,' Rodríguez said.
The drugs are marketed as 'good for your health, good for your image,' he added. 'That is exactly the risk for human health, because when you buy them, you are not really sure what they contain'.
The World Health Organization (WHO) and European Medicines Agency (EMA) have both warned in recent years that the black market is flourishing for counterfeit semaglutide, which is the active ingredient in blockbuster anti-obesity and diabetes medicines such as Ozempic and Wegovy.
Interpol said a single semaglutide pen can sell for hundreds of euros on the black market.
Meanwhile, peptide seizures were relatively rare until recently. The agency said the uptick in Europe, North America, and Oceania reflects a rise in demand for supplements such as BPC-157, ipamorelin, and melanotan, which are unproven products sold illegally as wellness, anti-ageing, or cosmetic aids.
Related
Weight loss drugs: New study sheds light on illegal online pharmacies selling Wegovy and Ozempic
Melanotan, for example, is a synthetic hormone designed to boost melanin production, giving people the appearance of tanned skin. Sometimes called the 'Barbie drug,' melanotan has taken off on platforms such as TikTok – but it is not regulated in Europe and health agencies have warned that it may cause serious health problems.
'With a lot of substances, the marketing is amplified by influencers, for instance in terms of health and culture,' Rodríguez said.
Worldwide, the most commonly seized illicit pharmaceuticals were psychostimulants, anti-anxiety drugs, and Parkinson's disease medicines, followed by erectile dysfunction drugs, Interpol said.
Other commonly seized counterfeit or otherwise illegal drugs include anabolic steroids, anti-smoking medicines, dermatological agents, health supplements, herbal products, and psychotropic medications for mental health conditions.
Police also confiscated the opioid painkiller oxycodone in Bulgaria, France, Ireland, and Sweden.
Related
Fake painkillers are circulating in the Netherlands, authorities warn after man dies
The sale of counterfeit medicines can have deadly consequences. In March, a 30-year-old man died after taking fake painkillers in the Netherlands, and last month, health authorities in Denmark warned that they were also circulating there.
'It seems that in the West, the demand for painkillers is rising… and criminals are taking advantage of it,' Rodríguez said.
As part of the Interpol operation, nearly 800 suspects were arrested and 123 criminal groups were dismantled. Police also took down about 13,000 websites, social media accounts, and bots that advertised and sold illegal or counterfeit medicines online.
Authorities in Ireland shuttered about 1,400 online listings for fake or illegal medicines, more than any other country except for Malaysia and Russia. Together with Singapore and Iran, the five countries accounted for 96 per cent of all listings that were taken down.
Related
Over 230 arrested as Europol dismantles four major drug smuggling networks
Ireland also saw large seizures of illegal medicines, as did the Netherlands, Portugal, Spain, Sweden, and the United Kingdom, according to Interpol.
In Portugal, for example, police discovered anabolic steroids in eight prisons, which Interpol said was evidence of a criminal smuggling network.
The agency noted that Europe-based criminals have easy access to the raw materials and infrastructure needed to run counterfeit drug production networks, meaning they can quickly adapt to changing trends and demand from consumers.
'It's a challenge for law enforcement agencies to follow this activity,' Rodríguez said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Got $200? 2 Biotech Stocks to Buy and Hold Forever
Good news for investors: You don't have to start out with tons of cash to grow wealth. Biotech stocks offer you a great opportunity to get in on innovators that may produce major growth down the road. 10 stocks we like better than Viking Therapeutics › Some potential investors hesitate to get started on building an investment portfolio because they think they need thousands of dollars to grow wealth. But I've got good news for them and for you: You don't have to start out with a huge pile of cash to invest in stocks that may significantly add value to your portfolio over time. In fact, with just $200, you can get in on players that could help you along the path to wealth. The industry of biotech is a great place to look for such stocks since so many of these companies are developing cutting-edge technologies that may lead to high-growth products, and revenue, down the road. Let's consider two that you might buy today -- a few shares of each for a total of $200 -- and hold forever to benefit from lasting growth stories. Viking Therapeutics (NASDAQ: VKTX) aims to make its mark in one of today's (and tomorrow's) biggest healthcare growth areas: weight loss drugs. The biotech company is developing a dual GIP/GLP-1 receptor agonist, known as VK2735, and has progressed into late-stage clinical trials. The candidate, in injectable form, just launched its phase 3 program and aims to enroll more than 4,000 participants with obesity and more than 1,000 volunteers with obesity and type 2 diabetes. VK2735 works by interacting with hormonal pathways involved in the control of appetite and blood sugar levels, much like the already commercialized Mounjaro and Zepbound, sold by Eli Lilly, and Ozempic and Wegovy, sold by Novo Nordisk. But the fact that similar drugs have reached the market first doesn't mean Viking can't succeed here. Demand for these sorts of products has been so high that it exceeded supply, until Lilly and Novo Nordisk increased manufacturing capacity. So there's plenty of room for a young company like Viking to succeed here too if all continues to go well in clinical trials. Viking also is testing VK2735 in oral form in a phase 2 trial, an important point since oral formulation could make these drugs easier to take, and it involves faster and cheaper manufacturing processes for the company. Data from that trial is expected later this year. Viking stock is known to soar on positive results. It surged more than 120% last year in just one trading session after reporting positive phase 2 data for VK2735. It's since given up the gains, offering investors a solid entry point, but any good news and a possible regulatory nod could prompt the stock to skyrocket. Moderna (NASDAQ: MRNA) used to be a favorite of investors during the early days of the coronavirus pandemic -- but since, it's had trouble bringing investors back into its potential growth story. The stock has lost more than 90% since its peak back in 2021, and the company has reported decreasing sales because of the drop in demand for its coronavirus vaccine and lower-than-expected sales of its more recently launched respiratory syncytial virus (RSV) vaccine. After Moderna's billions of dollars in revenue and profit just a couple of years ago and recent earnings declines, investors may find it difficult to get excited about Moderna again. But it's important to remember two things: First, it's unfair to compare revenue potential during ordinary times to revenue linked to a pandemic-related product. Those were exceptional times that don't occur often. Second, the approval of Moderna's coronavirus and RSV vaccines show that its technology -- the technology driving the rest of its pipeline -- works. The company now has many late-stage products in the works and aims to launch as many as 10 over the next few years. If Moderna even makes it partially to that goal, its revenue picture a few years from now may look very different from the picture today -- and set the company up for long-term growth. It's too early to predict when the market will recognize this and flock to Moderna shares. But at today's level, the stock offers investors a buying opportunity, making it a great place to park part of your $200 and hold on for the long-term as this growth story develops. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Moderna, Novo Nordisk, and Viking Therapeutics. The Motley Fool has a disclosure policy. Got $200? 2 Biotech Stocks to Buy and Hold Forever was originally published by The Motley Fool Sign in to access your portfolio
Los Angeles Times
an hour ago
- Los Angeles Times
Belarus frees more prisoners while simultaneously cracking down on dissent
TALLINN, Estonia — Belarus' authoritarian President Alexander Lukashenko announced pardons for 16 more prisoners on Wednesday, a gesture that comes as the unrelenting crackdown on dissent continues. The newly pardoned prisoners were convicted on a variety of criminal charges, including extremism — a charge often used against dissidents and government critics in Belarus. Human rights advocates welcomed the release of the prisoners, but stressed that it is taking place as more people are being arrested in politically driven cases. Last month, the Belarusian government pardoned and released 14 prisoners, but at least 60 more people were arrested on politically motivated charges, said Pavel Sapelka, a rights advocate with the Viasna Human Rights Centre, the country's oldest and most prominent rights group. Sapelka, in conversation with the Associated Press, compared the situation in Belarus to 'revolving doors, where new political prisoners take the place of those released.' Mass arrests and convictions of government critics in Belarus have continued since 2020, when Lukashenko was handed a sixth term in office in an election that the opposition and the West denounced as rigged. Tens of thousands of people took to the streets in protest, in the biggest demonstrations that the country had ever seen. Authorities unleashed a violent crackdown, detaining and beating thousands and driving many more into exile abroad. The suppression of dissent drew international condemnation, and the U.S. and the European Union imposed sanctions on Belarus. As of Wednesday, Viasna has designated 1,164 people behind bars as political prisoners. The number includes 38 journalists and the group's founder, Ales Bialiatski, who won the Nobel Peace Prize in 2022. At least eight political prisoners have died behind bars. Lukashenko, who in January secured another term in office in another election the opposition denounced as a sham, has recently been pardoning some political prisoners, seeking to improve ties with the West. In total, he has pardoned and freed more than 300 prisoners since July 2024, including some U.S. citizens and other foreigners. Last month, Belarusian authorities released prominent opposition figure Siarhei Tsikhanouski and 13 others, and brought them to Lithuania. Their release came just hours after Belarusian authorities announced that Lukashenko met with President Trump's envoy for Ukraine, Keith Kellogg, in the Belarusian capital, Minsk. Commenting on the high-profile release on Tuesday evening, Lukashenko said 'God forbid' those freed last month died behind bars. 'We would have been blamed for doing it to them,' he said. 'So it's politics.' Sapelka told AP on Wednesday that there likely aren't any prominent dissidents among the 16 newly released prisoners. Karmanau writes for the Associated Press.
Miami Herald
4 hours ago
- Miami Herald
Man receives kidney transplant, then body becomes riddled with worms, doctors say
Ten weeks after a New England man received a kidney transplant, he went into respiratory failure and shock — thanks to an extensive parasitic worm infection, according to his medical team. The 61-year-old man received a new kidney from a deceased donor after being diagnosed with 'nephrosclerosis-related end-stage kidney disease,' or chronic high blood pressure that causes hardening of the walls of arteries in the kidneys, according to a June 18 case report published in the Case Records of the Massachusetts General Hospital. The transplant was successful and the man was sent home with care instructions just four days later, doctors said. Six weeks later, the man attended a follow-up visit where doctors saw a slightly elevated creatinine level and hyperglycemia, the former an indicator of kidney function and the latter indicative of diabetes, according to the report. He was sent home with a weekly injection of semaglutide, the active ingredient in drugs like Ozempic and Wegovy. Then his health took a turn. Successful transplant turns critical A week later, the 61-year-old was scratched by his cat and his ankle began to swell, doctors said. He started to feel tired and nauseated the next week, then started throwing up and drinking excessive amounts of water, according to the case report. He was admitted to the hospital again, and over the next ten days, his heart rate increased significantly, his breathing decreased until he needed to be put on a ventilator, doctors said. Hoping for answers, his medical team turned to his previous medical history for something that might have been missed. The 61-year-old had been on the transplant list for 6 years, according to the report, and he had diabetes and spent much of his life as a smoker. He had lived in New England his entire life and hadn't traveled. He enjoyed gardening, and had healthy cats and a dog at home with his wife. Then the rash appeared. Purple and blotchy, the rash stretched across his stomach as his abdomen grew to become large and hard, and normal bowel sounds were absent, according to the report. By this point, the man was described as 'critically ill,' and because the man was on immunodepressants to help his body transition to the new organ, doctors compared the man's symptoms to other examples of infections. 'Given that the patient's presentation is not consistent with a drug reaction or rejection of the kidney allograft, I think that the most likely explanation for his critical illness is a disseminated parasitic infection,' Camille N. Kotton, an infectious disease and transplant expert, wrote in the report. The man was diagnosed with 'donor-derived disseminated strongyloidiasis,' or an infection caused by parasitic roundworms, doctors said. What are roundworms? The roundworms, also called threadworms, can infect humans directly, but can also be passed to humans through contact with monkeys or domestic dogs, according to the Centers for Disease Control and Prevention. In this man's case, the source of the infection was his new kidney, donated from someone who lived in the Caribbean before their death and who had not been tested for strongyloides before the donation, according to the case report. Between 2008 and 2017, the Organ Procurement and Transplantation Network, the group that oversees organ donation in the United States, reported 14 out of 10,000 organ donations could result in disease transmission, or about 0.14% of donations, doctors said. 'Unfortunately, many of these events are varied and unexpected, involving a long list of pathogens ranging from viruses to bacteria and parasites,' doctors wrote. 'Although we have contemplated how to avoid such transmissions, many seem unavoidable and result in undesirable circumstances.' The man was successfully treated with ivermectin, an antiparasitic drug, and doctors contacted the organ board to see if any other patients had received organs from the same donor, according to the report. A 66-year-old man had received the donor's other kidney, doctors said, and his medical team was contacted to begin treatment for the infection after he had already been showing similar symptoms. Both men fully recovered and their transplants were successful, according to the report. The medical team includes Kotton, Rory L. Cochran, Alan M. Sanders, Kassem Safa and Maxwell T. Roth.
